Search: onr:"swepub:oai:prod.swepub.kib.ki.se:150296930" >
Targeted Therapy of...
Targeted Therapy of HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy between CDK4/6, PI3K and Sometimes FGFR Inhibitors, but Rarely between PARP and WEE1 Inhibitors
-
- Kostopoulou, ON (author)
- Karolinska Institutet
-
- Zupancic, M (author)
- Karolinska Institutet
-
Pont, M (author)
-
show more...
-
Papin, E (author)
-
- Lukoseviciute, M (author)
- Karolinska Institutet
-
Mikelarena, BA (author)
-
- Holzhauser, S (author)
- Karolinska Institutet
-
- Dalianis, T (author)
- Karolinska Institutet
-
show less...
-
(creator_code:org_t)
- 2022-06-23
- 2022
- English.
-
In: Viruses. - : MDPI AG. - 1999-4915. ; 14:7
- Related links:
-
http://kipublication...
-
show more...
-
https://doi.org/10.3...
-
show less...
Abstract
Subject headings
Close
- Human papillomavirus positive (HPV+) tonsillar and base of tongue squamous cell carcinoma (TSCC/BOTSCC) have a favorable outcome, but upon relapse, survival is poor and new therapeutical options are needed. Recently, we found synergistic effects by combining the food and drug administration approved (FDA) phosphoinositide 3-kinase (PI3K) and fibroblast-growth-factor-receptor (FGFR) inhibitors BYL719 and JNJ-42756493 on TSCC cell lines. Here this approach was extended and Cyclin-Dependent-Kinase-4/6 (CDK4/6) and Poly-ADP-ribose-polymerase (PARP) and WEE1 inhibitors PD-0332991, and MK-1775 respectively were also examined. HPV+ CU-OP-2, -3, -20, and HPV− CU-OP-17 TSCC cell lines were treated with either BYL719 and JNJ-42756493, PD-0332991 BMN-673 and MK-1775 alone or in different combinations. Viability, proliferation, and cytotoxicity were followed by WST-1 assays and the IncuCyte S3 Live® Cell Analysis System. All inhibitors presented dose-dependent inhibitory effects on tested TSCC lines. Synergy was frequently obtained when combining CDK4/6 with PI3K inhibitors, but only sometimes or rarely when combining CDK4/6 with FGFR inhibitors or PARP with WEE1 inhibitors. To conclude, using CDK4/6 with PI3K or FGFR inhibitors, especially PD-0332991 with BYL719 presented synergy and enhanced the decrease of viability considerably, while although dose dependent responses were obtained with PARP and WEE1 inhibitors (BMN-673 and MK-1775 resp.), synergy was rarely disclosed.
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
-
Viruses
(Search for host publication in LIBRIS)
To the university's database